Ortec tests Fibrin Microbead technology for stem-cell regeneration in bone defects

By Elaine Rigoli

Tampa, Fla., June 22 - Ortec International, Inc. has begun a preclinical study in rabbits to evaluate the capabilities of the Fibrin Microbead system to accomplish the full cycle of steps required to use a patient's own stem cells therapeutically to regenerate large gaps in long bone tissue.

"The launch of this study is another key step toward accelerating the development and commercialization of the practical tissue regeneration therapeutic capabilities of our recently acquired Fibrin Microbead technology. We expect this study will provide us with the data from which we can design a clinical protocol and initiate a human clinical trial for this orthopedic indication," chief executive officer and vice chairman Ron Lipstein said in a news release.

The Fibrin Microbead technology is a proprietary matrix for the isolation, expansion and differentiation of matrix-dependent cells, including Mesenchymal-type adult stem cells, and their potential reimplantation into the patient, the release said.

Complete study results are expected within six to eight months.

New York-based Ortec provides regenerative medicine and stem cell therapy products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.